{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Aptamer", "Calcium phosphate nanoparticles", "Concentration inhibitrice", "Diab\u00e8te de type 2", "Inhibitory concentration", "Nanoparticules de phosphate de calcium", "Prot\u00e9ine de liaison au r\u00e9tinol4", "Retinol binding protein 4", "Type 2 diabetes"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "28279618", "DateCompleted": {"Year": "2018", "Month": "03", "Day": "08"}, "DateRevised": {"Year": "2018", "Month": "03", "Day": "08"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "03", "Day": "06"}], "Language": ["eng"], "ELocationID": ["10.1016/j.jcjd.2016.11.001", "S1499-2671(16)30511-1"], "Journal": {"ISSN": "2352-3840", "JournalIssue": {"Volume": "41", "Issue": "3", "PubDate": {"Year": "2017", "Month": "Jun"}}, "Title": "Canadian journal of diabetes", "ISOAbbreviation": "Can J Diabetes"}, "ArticleTitle": "Aptamer-Conjugated Calcium Phosphate Nanoparticles for Reducing Diabetes Risk via Retinol Binding Protein 4 Inhibition.", "Pagination": {"StartPage": "305", "EndPage": "311", "MedlinePgn": "305-311"}, "Abstract": {"AbstractText": ["Inhibition of the binding of retinol to its carrier, retinol binding protein 4, is a new strategy for treating type 2 diabetes; for this purpose, we have provided an aptamer-functionalized multishell calcium phosphate nanoparticle.", "First, calcium phosphate nanoparticles were synthesized and conjugated to the aptamer. The cytotoxicity of nanoparticles releases the process of aptamer from nanoparticles and their inhibition function of binding retinol to retinol binding protein 4.", "After synthesizing and characterizing the multishell calcium phosphate nanoparticles and observing the noncytotoxicity of conjugate, the optimum time (48 hours) and the pH (7.4) for releasing the aptamer from the nanoparticles was determined. The half-maximum inhibitory concentration (IC<sub>50</sub>) value for inhibition of retinol binding to retinol binding protein 4 was 210 femtomolar (fmol).", "The results revealed that the aptamer could prevent connection between retinol and retinol binding protein 4 at a very low IC<sub>50</sub> value (210 fmol) compared to other reported inhibitors. It seems that this aptamer could be used as an efficient candidate not only for decreasing the insulin resistance in type 2 diabetes, but also for inhibiting the other retinol binding protein 4-related diseases."], "CopyrightInformation": "Copyright \u00a9 2017 Diabetes Canada. Published by Elsevier Inc. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Microanalysis, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran."}], "LastName": "Torabi", "ForeName": "Raheleh", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Microanalysis, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran; Nanobiomedicine Center of Excellence, Nanoscience and Nanotechnology Research Center, University of Tehran, Tehran, Iran. Electronic address: ghourchian@ut.ac.ir."}], "LastName": "Ghourchian", "ForeName": "Hedayatollah", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, Faculty of Pharmacy and Medicinal Plants Research Center, Tehran University of Medical Sciences, Tehran, Iran; Nanobiomedicine Center of Excellence, Nanoscience and Nanotechnology Research Center, University of Tehran, Tehran, Iran."}], "LastName": "Amanlou", "ForeName": "Massoud", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Endocrinology and Metabolism Molecular Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Pasalar", "ForeName": "Parvin", "Initials": "P"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Canada", "MedlineTA": "Can J Diabetes", "NlmUniqueID": "101148810", "ISSNLinking": "1499-2671"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Aptamers, Nucleotide"}, {"RegistryNumber": "0", "NameOfSubstance": "Calcium Phosphates"}, {"RegistryNumber": "0", "NameOfSubstance": "RBP4 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Retinol-Binding Proteins, Plasma"}, {"RegistryNumber": "97Z1WI3NDX", "NameOfSubstance": "calcium phosphate"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["administration & dosage", "chemistry", "metabolism"], "DescriptorName": "Aptamers, Nucleotide"}, {"QualifierName": ["administration & dosage", "chemistry", "metabolism"], "DescriptorName": "Calcium Phosphates"}, {"QualifierName": ["metabolism"], "DescriptorName": "Diabetes Mellitus, Type 2"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "NIH 3T3 Cells"}, {"QualifierName": ["administration & dosage", "chemistry", "metabolism"], "DescriptorName": "Nanoparticles"}, {"QualifierName": ["physiology"], "DescriptorName": "Protein Binding"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Retinol-Binding Proteins, Plasma"}, {"QualifierName": [], "DescriptorName": "Risk Factors"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2016", "Month": "8", "Day": "24"}, {"Year": "2016", "Month": "10", "Day": "11"}, {"Year": "2016", "Month": "11", "Day": "1"}, {"Year": "2017", "Month": "3", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "3", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "3", "Day": "11", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["28279618", "10.1016/j.jcjd.2016.11.001", "S1499-2671(16)30511-1"]}}]}